Oncopeptides AB Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- Oncopeptides AB's estimated annual revenue is currently $15.9M per year.
- Oncopeptides AB's estimated revenue per employee is $201,000
- Oncopeptides AB has 79 Employees.
- Oncopeptides AB grew their employee count by 93% last year.
- Oncopeptides AB currently has 1 job openings.
What Is Oncopeptides AB?
Oncopeptides is a late stage clinical development pharmaceutical company focused on bringing anti-cancer research as treatments for the benefit of patients. The company was established in 2000 and is based in Stockholm, Sweden. Oncopeptides has developed Ygalo, the first targeted cytotoxic therapy intended for use in the treatment of multiple myeloma. The first indication is late-stage relapsed and refractory multiple myeloma. Ygalo is unique in its ability to kill cancer cells up to fifty-times better than exiting cytotoxic treatments, without a similar increase in effect on the patient's bone marrow, as demonstrated in clinical and pre-clinical studies. Comparing clinical data between Ygalo and the current standard of care in late-stage multiple myeloma indicates that treatment with Ygalo increases overall survival, progression free survival and the number of patients with significant tumour burden reduction as well as being better tolerated by patients. Ygalo has undergone the US Food and Drug Administration's Special Protocol Assessment process for a pivotal Phase III study of patients with late-stage multiple myeloma. The study, called OCEAN, will start in H1 2017 and will compare Ygalo directly against the current standard of care. The successful conclusion of this study will likely lead to regulatory approval in the US and Europe. There is also a phase II study called HORIZON and a phase I/II study called ANCHOR in progress. Each year, approximately three in every 10,000 people are diagnosed with multiple myeloma. As there is no cure for multiple myeloma, a key focus of treatment is extending and improving the quality of life for patients. In 2016, global sales of the current standard of care for comparable late-stage multiple myeloma patients represented approximately USD 1.3 billion. This market is expected to grow to a value of USD 2.3 billion by 2019 driven mainly by an ageing population and improved treatments.keywords:N/A